RIDGEFIELD – The biopharmaceutical company Boehringer Ingelheim will invest $10 billion through 2028 to expand its pharmaceutical R&D and manufacturing operations in the U.S. The agreement excludes the German pharmaceutical maker from potential U.S. tariffs.
The company announced the agreement Friday, Dec. 19, with the Trump Administration to lower the cost of medicines for American patients, in line with the conditions set out by President Trump in his letter to the pharmaceutical industry dated July 31, 2025. This includes participating in a direct purchasing platform, TrumpRx.gov, that will allow American patients to purchase medicines from Boehringer at a significant discount.
Boehringer’s investment includes $1 billion dedicated specifically for capital expenditures. It is also part of Boehringer’s broader six-year plan to invest $20 billion across both its human pharmaceuticals and animal health businesses in the U.S.
“Boehringer Ingelheim has a long history of addressing chronic diseases and supporting patients in their care journey,” said Jean-Michel Boers, president and CEO, Boehringer Ingelheim, USA Corporation based in Ridgefield. “Around 70 million Americans are suffering from cardiovascular, renal, metabolic diseases, and of those, 35 million have chronic kidney disease (CKD). Most are unaware and won’t find out they have CKD until damage is done, leading to poor health outcomes.”
Boers thanked President Trump for the “constructive engagement” to achieve lower costs for medicines, as well as increased investment in the U.S. pharmaceutical sector, leading to more American jobs.
Shashank Deshpande, Boehringer Ingelheim’s chair, emphasized the importance of the agreement to strengthen the company’s supply chain.
“Today’s voluntary agreement strengthens the supply chain for life-changing medicines, while reinforcing the foundations for medical innovation in the U.S.,” Deshpande said. “We must now strengthen the resilience and sustainability of health systems worldwide to ensure pharmaceutical innovation can continue to thrive.”
While Boehringer’s human pharma headquarters is based in Ridgefield, its animal pharma headquarters is in Georgia. In the U.S., the company’s footprint extends to more than 20 sites nationwide including manufacturing facilities, R&D centers and partner locations.
